Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-81201887 for Geographic Atrophy
NCT05811351Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2023
- Primary completion
- Feb 2026
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 17
01
Overview
Phase 2, randomised, double-blind trial of JNJ-81201887 in geographic atrophy (GA), sponsored by Janssen Pharmaceutical. Primary endpoints: Change From Baseline in Square Root of Geographic Atrophy Lesion Area at 18 months and Rate of Change in Untransformed Geographic Atrophy Lesion Area at 18 months. Started Mar 2023; status: completed.
02
Drugs
JNJ-81201887
03
Conditions
geographic atrophy (GA)
Beyond the preview
Go deeper on NCT05811351.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05811351.